Insmed Incorporated
NASDAQ:INSMBiotechnology
-$2.73 today
- Market cap
- $26.28B
- Beta
- 0.77
- P/E (TTM)
- -17.4
- EPS (TTM)
- -$5.49
Volume 1.94M
Average 3.31M
INSM Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Insmed IncorporatedNASDAQ: INSM
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income declines year over year
Q2 FY2026 net income of $13.24M (cash outflow) fell 95.9% year over year, behind the -15.4% change in trailing-twelve-month net income. Sequentially, it fell 91.9% from the prior quarter. Over 3 fiscal years it compounded at +38.4% a year.
Context
- Net income amounted to 210.5% of revenue in FY2025, down 40.7 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 15 analysts of -$363.59M (-71.5%) for the fiscal year ending Dec 2026, a slowdown from the +39.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$13.24M-91.9% QoQ
- Last fiscal yearDec 2025
- -$1.28B+39.7% YoY
- LTMJun 2026
- -$875.31M-15.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -95.9% | -77.4% | +18.5 pp |
| 1 year | +39.7% | -71.5% | -111.2 pp |
| 3-year CAGR | +38.4% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (1.28B) USD
- Year-over-year change
- -39.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.28B) | -39.7% |
| FY2024 | 2024-12-31 | (913.77M) | -21.9% |
| FY2023 | 2023-12-31 | (749.57M) | -55.7% |
| FY2022 | 2022-12-31 | (481.53M) | -10.8% |
| FY2021 | 2021-12-31 | (434.65M) | — |
Net Income vs competitors
How INSM compares with its peers on the latest reported figures
- INSM's LTM Jun 2026 net income of $875.31M is the 2nd largest of the 4 companies compared; the peer median is $114.54M.
- Its year-over-year change of -15.4% is the lowest of 4, against a peer median of +111.9%.
- Net income amounts to 76.9% of revenue for INSM, versus a peer median of 41.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.31B | +5.5% | +22.4% | 41.6% | |
| LTM Jun 2026 | $875.31M | -15.4% | +38.4% | 76.9% | |
| LTM Mar 2026 | $114.54M | +296.4% | — | 104.3% | |
| LTM Jun 2026 | $16.82M | +111.9% | +18.9% | 3.7% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding INSM) | $114.54M | +111.9% | +20.7% | 41.6% | |
Competitors are the stored peer set for INSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (434.65M) | (481.53M) | (749.57M) | (913.77M) | (1.28B) |
| Depreciation & Amortization | 14.18M | 10.33M | 10.58M | 11.01M | 16.45M |
| Deferred Income Tax | 17.69M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 46.02M | 57.69M | 74.78M | 96.84M | 152.71M |
| Change in Working Capital | (58.58M) | 6.58M | (39.22M) | (3.18M) | (80.3M) |
| Accounts Receivables | (8.12M) | (6.42M) | (11.96M) | (12.93M) | (88.31M) |
| Inventory | (17.46M) | (1.71M) | (13.61M) | (17.04M) | (31.52M) |
| Accounts Payables | (7.58M) | 50.01M | 15.16M | 44.59M | 100.07M |
| Other Working Capital | (25.43M) | (35.3M) | (28.8M) | (17.79M) | (60.55M) |
| Other Non-Cash Items | 52.04M | 6.5M | 167.18M | 125.22M | 252.9M |
| Operating Cash Flow | (363.3M) | (400.44M) | (536.25M) | (683.88M) | (935.01M) |
| Capital Expenditures | (7.29M) | (9.88M) | (13.29M) | (21.92M) | (32.56M) |
| Acquisitions (Net) | (6.7M) | 24.71M | 3.42M | 0 | 0 |
| Purchases of Investments | (50.29M) | (99.71M) | (588.73M) | (1.58B) | (2.09B) |
| Sales of Investments | 57M | 75M | 375M | 1.02B | 2.09B |
| Other Investing Activities | (57M) | (24.71M) | 0 | 0 | (30M) |
| Investing Cash Flow | (64.29M) | (34.58M) | (223.6M) | (583.18M) | (64.58M) |
| Debt Repayment | 336.34M | 349.4M | (1.22M) | 147.39M | (4.93M) |
| Common Stock Issued | 269.89M | 292.15M | 152.48M | 1.08B | 959M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.32M | 151.72M | 17.18M | 109.51M | 0 |
| Financing Cash Flow | 612.55M | 793.27M | 168.44M | 1.34B | 954.07M |
| Effect of Forex Changes | (933K) | (996K) | (250K) | (1.31M) | 931K |
| Net Change in Cash | 184.03M | 357.25M | (591.66M) | 72.66M | (44.59M) |
| Free Cash Flow | (370.59M) | (410.32M) | (549.54M) | (705.81M) | (967.58M) |
Insmed Incorporated
NASDAQ:INSM
Intrinsic Alpha fair value
Locked
Current Price
$119.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.